Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

UniQure's Huntington's Gene Therapy Shows Promising Results, Setting Stage for FDA Submission

UniQure's Huntington's Gene Therapy Shows Promising Results, Setting Stage for FDA Submission

UniQure has announced groundbreaking results from its phase 1/2 trial of AMT-130, a gene therapy for Huntington's disease, potentially paving the way for the first genetic treatment for this devastating neurodegenerative disorder. The therapy demonstrated a significant 75% slowing of disease progression after three years, exceeding expectations and positioning the company for a biologics license application (BLA) submission to the FDA in early 2026.

NoahAI News9/25/2025
Fujifilm Biotechnologies Unveils $3.2B Antibody Facility in North Carolina, Ushering in New Era of Biomanufacturing

Fujifilm Biotechnologies Unveils $3.2B Antibody Facility in North Carolina, Ushering in New Era of Biomanufacturing

Fujifilm Biotechnologies has officially opened its highly anticipated $3.2 billion cell culture facility in Holly Springs, North Carolina, marking a significant milestone in the company's expansion and the broader landscape of U.S. biomanufacturing. The state-of-the-art plant, which focuses on antibody-based drugs, is poised to become one of the largest cell culture biomanufacturing sites in the United States.

NoahAI News9/25/2025
FDA Rejects Two Spinal Muscular Atrophy Therapies Over Manufacturing Concerns

FDA Rejects Two Spinal Muscular Atrophy Therapies Over Manufacturing Concerns

In a surprising turn of events, the U.S. Food and Drug Administration (FDA) has denied approval for two spinal muscular atrophy (SMA) therapies on the same day, citing manufacturing issues in both cases. The rejections have sent ripples through the pharmaceutical industry, highlighting the critical importance of manufacturing processes in drug development and approval.

NoahAI News9/25/2025
Heartflow's AI for Coronary Plaque Analysis Receives FDA Clearance and Expanded Insurance Coverage

Heartflow's AI for Coronary Plaque Analysis Receives FDA Clearance and Expanded Insurance Coverage

Heartflow, a leading medical technology company, has achieved significant milestones in the development and commercialization of its artificial intelligence (AI) platform for coronary plaque analysis. The company's latest advancements include FDA clearance for an updated version of its AI software and expanded insurance coverage, marking important steps forward in cardiovascular diagnostics and patient care.

NoahAI News9/25/2025
AI-Powered Scheduling Agents Revolutionize Outpatient Clinic Operations

AI-Powered Scheduling Agents Revolutionize Outpatient Clinic Operations

UnityAI, a Nashville-based AI operations startup, has launched specialized voice AI agents designed to streamline scheduling and patient communication processes in outpatient clinics. This development marks a significant shift in how healthcare facilities manage their day-to-day operations, potentially reducing costs and improving efficiency.

NoahAI News9/25/2025
Acadia Discontinues Prader-Willi Drug After Phase 3 Trial Failure

Acadia Discontinues Prader-Willi Drug After Phase 3 Trial Failure

Acadia Pharmaceuticals has announced the discontinuation of its drug candidate ACP-101 for treating hyperphagia associated with Prader-Willi syndrome following disappointing results from a Phase 3 clinical trial. The setback removes a potential competitor to Soleno Therapeutics' recently approved treatment, Vykat XR.

NoahAI News9/25/2025
Future Family Appoints New CEO, Expands IVF Financing and Insurance Offerings

Future Family Appoints New CEO, Expands IVF Financing and Insurance Offerings

Future Family, a leading provider of financing solutions for in vitro fertilization (IVF) treatments, has announced the appointment of Alden Romney as its new CEO. The company, which has extended over $200 million in financing to more than 10,000 families since its inception in 2016, is poised for further growth in the fertility care sector.

NoahAI News9/25/2025
Lantheus and GE HealthCare Forge Strategic Partnership for Prostate Cancer Imaging in Japan

Lantheus and GE HealthCare Forge Strategic Partnership for Prostate Cancer Imaging in Japan

Lantheus, a leader in diagnostic and therapeutic radiopharmaceuticals, has entered into a significant agreement with GE HealthCare, granting the latter rights to its blockbuster prostate cancer PET imaging agent, Pylarify, in Japan. This strategic move aims to expand the reach of the diagnostic tool in key international markets, leveraging GE HealthCare's recent acquisition of Nihon Medi-Physics (NMP), a prominent radiopharmaceutical provider in Japan.

NoahAI News9/25/2025
Biopharma Deal Structures Shift: Upfront Payments Rise as Earnout Potentials Decline

Biopharma Deal Structures Shift: Upfront Payments Rise as Earnout Potentials Decline

In a notable trend reshaping the landscape of pharmaceutical industry deals, recent data from SRS Acquiom reveals a significant shift in how biopharma agreements are structured. The analysis, covering deals from mid-2023 to mid-2025, shows a decline in average earnout potentials while upfront payments continue to rise, signaling a change in risk allocation between buyers and sellers in the biotech sector.

NoahAI News9/25/2025
Biopharma Layoffs Surge in 2025 Amid Strategic Restructuring

Biopharma Layoffs Surge in 2025 Amid Strategic Restructuring

Pharmaceutical Industry Layoffs Continue Amid Strategic Shifts and Pipeline ReprioritizationThe pharmaceutical and biotech sectors continue to face significant headwinds in 2025, with numerous companies announcing workforce reductions and strategic realignments. These moves come as firms grapple with challenging market conditions, pipeline setbacks, and the need to allocate resources more efficiently.

NoahAI News9/25/2025
Indian Generics Makers to Produce Affordable Versions of Gilead's HIV PrEP Drug Yeztugo

Indian Generics Makers to Produce Affordable Versions of Gilead's HIV PrEP Drug Yeztugo

In a significant development for global HIV prevention efforts, Indian generic pharmaceutical companies have secured agreements to manufacture and distribute more affordable versions of Gilead Sciences' twice-yearly HIV pre-exposure prophylaxis (PrEP) drug, Yeztugo (lenacapavir). These partnerships aim to increase access to the long-acting injectable medication in low- and middle-income countries, potentially revolutionizing HIV prevention strategies worldwide.

NoahAI News9/25/2025
Sparrow Pharmaceuticals Secures $95M Series B for Diabetes Treatment Development

Sparrow Pharmaceuticals Secures $95M Series B for Diabetes Treatment Development

Sparrow Pharmaceuticals, a Portland, Oregon-based biotech company, has announced a significant boost to its diabetes treatment research with a $95 million series B funding round. The investment, led by RA Capital Management and Forbion, with participation from existing investors OrbiMed, RiverVest, and US Venture Partners, will primarily support the ongoing phase 2b trial of the company's oral small molecule, clofutriben.

NoahAI News9/25/2025
«1...636465...67»